Lantern Pharma Inc (NASDAQ: LTRN)’s stock price has dropped by -10.36 in relation to previous closing price of 5.50. Nevertheless, the company has seen a loss of -13.81% in its stock price over the last five trading days. Seeking Alpha reported 2024-03-18 that Lantern Pharma Inc. (LTRN) Q4 2023 Earnings Call Transcript
Is It Worth Investing in Lantern Pharma Inc (NASDAQ: LTRN) Right Now?
The 36-month beta value for LTRN is also noteworthy at 1.52. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for LTRN is 7.86M, and at present, short sellers hold a 6.33% of that float. The average trading volume of LTRN on April 30, 2024 was 319.37K shares.
LTRN’s Market Performance
The stock of Lantern Pharma Inc (LTRN) has seen a -13.81% decrease in the past week, with a -43.98% drop in the past month, and a 16.27% gain in the past quarter. The volatility ratio for the week is 10.60%, and the volatility levels for the past 30 days are at 11.83% for LTRN. The simple moving average for the past 20 days is -27.25% for LTRN’s stock, with a 5.67% simple moving average for the past 200 days.
Analysts’ Opinion of LTRN
Many brokerage firms have already submitted their reports for LTRN stocks, with H.C. Wainwright repeating the rating for LTRN by listing it as a “Buy.” The predicted price for LTRN in the upcoming period, according to H.C. Wainwright is $32 based on the research report published on October 07, 2021 of the previous year 2021.
LTRN Trading at -26.06% from the 50-Day Moving Average
After a stumble in the market that brought LTRN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -58.88% of loss for the given period.
Volatility was left at 11.83%, however, over the last 30 days, the volatility rate increased by 10.60%, as shares sank -48.16% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +22.94% upper at present.
During the last 5 trading sessions, LTRN fell by -13.81%, which changed the moving average for the period of 200-days by -5.19% in comparison to the 20-day moving average, which settled at $6.55. In addition, Lantern Pharma Inc saw 15.19% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at LTRN starting from Kreis Leslie W., who sale 19,703 shares at the price of $4.87 back on Feb 29 ’24. After this action, Kreis Leslie W. now owns 60,256 shares of Lantern Pharma Inc, valued at $95,954 using the latest closing price.
Fletcher Aaron G.L., the 10% Owner of Lantern Pharma Inc, sale 19,703 shares at $4.87 during a trade that took place back on Feb 29 ’24, which means that Fletcher Aaron G.L. is holding 60,256 shares at $95,954 based on the most recent closing price.
Stock Fundamentals for LTRN
The total capital return value is set at -0.44. Equity return is now at value -32.93, with -31.15 for asset returns.
Based on Lantern Pharma Inc (LTRN), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -61.19. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is 42.72.
Currently, EBITDA for the company is -17.7 million with net debt to EBITDA at 1.22. The liquidity ratio also appears to be rather interesting for investors as it stands at 16.18.
Conclusion
In summary, Lantern Pharma Inc (LTRN) has had a mixed performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
